Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
Markus M Borner, Daniel Dietrich, Roger Stupp, et al.
Swiss Medical Weekly
|
March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Sandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
BMC Cancer
|
February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Journal of Bone Oncology
|
January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Michael Mark, Beat Thürlimann, Karin Ribi, et al.
Blood
|
February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial
Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
Arnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Journal of Geriatric Oncology
|
December 19, 2018
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Dirk L Kienle, Daniel Dietrich, Karin Ribi, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2015
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System
Herman Autrup, Frank A Barile, Bas J Blaauboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
Markus M Borner, Daniel Dietrich, Roger Stupp, et al.
Swiss Medical Weekly
|
March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Sandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
BMC Cancer
|
February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Journal of Bone Oncology
|
January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Michael Mark, Beat Thürlimann, Karin Ribi, et al.
Blood
|
February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial
Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
Arnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Journal of Geriatric Oncology
|
December 19, 2018
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Dirk L Kienle, Daniel Dietrich, Karin Ribi, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2015
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System
Herman Autrup, Frank A Barile, Bas J Blaauboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Page
of 7